Cyclophosphamide and lupus nephritis: When, how, for how long?

Clinical Reviews in Allergy and Immunology

Volumn 40, Issue 3, 2011, Pages 181-191

  Ntali, Stella ^a   Bertsias, George ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Induction therapy; Lupus nephritis; Maintenance therapy; Randomized controlled trials

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

CHILD CARE; CLINICAL RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTOXICATION; DRUG MEGADOSE; GONADAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NAUSEA AND VOMITING; NEOPLASM; REVIEW;

CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GONADAL DISORDERS; HUMANS; IMMUNOSUPPRESSION; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 79959241934     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-009-8196-0     Document Type: Review

References (42)

1. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ (1987) Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 47:2723-2726 (Pubitemid 17083165)
2. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495-1501 (Pubitemid 34304511)
3. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM (1978) Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151-1155 (Pubitemid 9065570)
4. Austin HA 3rd, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619 (Pubitemid 16132725)
5. Boumpas DT, Austin HA 3rd, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
6. Gourley MF, Austin HA 3rd, Scott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549-557 (Pubitemid 126450087)
7. Illei GG, Austin HA, Crane M et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248-257 (Pubitemid 32799338)
8. Houssiau FA, Vasconcelos C, D'Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131
9. Houssiau FA, Vasconcelos C, D'Cruz D et al (2010) The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61-64
10. Chan TM, Li FK, Hao WK et al (1999) Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8:545-551 (Pubitemid 29452568)
11. Austin HA, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901-911
12. Mok CC, Ying KY, Ng WL et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119(355):e25-e33
13. de Groot K, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670-680
14. Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156-1162
15. Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076-1084 (Pubitemid 41710318)
16. Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980 (Pubitemid 38269274)
17. Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219-2228 (Pubitemid 41697285)
18. Ong LM, Hooi LS, Lim TO et al (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10:504-510 (Pubitemid 41727277)
19. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS (2009) Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 48:944-952
20. Grootscholten C, Ligtenberg G, Hagen EC et al (2006) Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732-742 (Pubitemid 44215349)
21. Grootscholten C, Bajema IM, Florquin S et al (2007) Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 56:924-937 (Pubitemid 46399440)
22. Bosch X, Guilabert A, Pallares L et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584-589 (Pubitemid 44661745)
23. Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39:1475-1482 (Pubitemid 26314980)
24. Ramos-Casals M, Cuadrado MJ, Alba P et al (2008) Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 87:311-318
25. Mosca M, Tani C, Aringer M et al (2009) EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis (in press)
26. Bernatsky S, Clarke AE, Ramsey-Goldman R (2008) Cancer in systemic lupus: what drives the risk? Cancer Causes Control 19:1413-1414
27. Turnbull J, Harper L (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23:391-401
28. Ognenovski VM, Marder W, Somers EC et al (2004) Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 31:1763-1767 (Pubitemid 39202518)
29. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-369 (Pubitemid 23310085)
30. Rivkees SA, Crawford JD (1988) The relationship of gonadal activity and chemotherapy-induced gonadal damage. Jama 259:2123-2125 (Pubitemid 18088500)
31. Raptopoulou A, Sidiropoulos P, Boumpas D (2004) Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13:887-890 (Pubitemid 39664945)
32. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M (2000) Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9:401-405 (Pubitemid 30487421)
33. von Scheven E, Bakkaloglu A (2009) What's new in paediatric SLE? Best Pract Res Clin Rheumatol 23:699-708
34. Lehman TJ, Sherry DD, Wagner-Weiner L et al (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114:1055-1060 (Pubitemid 19151774)
35. Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243-247 (Pubitemid 30470998)
36. Lau KK, Ault BH, Jones DP, Butani L (2008) Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 22:282-288
37. Askenazi D, Myones B, Kamdar A et al (2007) Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 22:981-986 (Pubitemid 46881916)
38. Demircin G, Oner A, Erdogan O et al (2008) Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis. Ren Fail 30:603-609
39. Benseler SM, Bargman JM, Feldman BM et al (2009) Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 48:176-182
40. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556-562 (Pubitemid 351294890)
41. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS (2008) Successful treatment of class V+IV lupus nephritis with multi-target therapy. J Am Soc Nephrol 19:2001-2010
42. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103-1112